United States Patent US 10,646,500: Scope, Claims, and Competitive Landscape
US 10,646,500 is directed to treating allergic rhinitis in a human by nasal administration of a fixed-dose combination of mometasone furoate (MF) and olopatadine hydrochloride (OLP) in a specific metered spray regimen and specific dose per spray, with a central limitation that the combination at twice-daily dosing produces faster onset of action than twice-daily dosing of olopatadine alone.
What do the claims cover (and what is the core infringement hook)?
1) Independent claim 1: broadest scope
Claim 1 covers:
- Indication/scope of patients: “one or more symptoms associated with allergic rhinitis in a human subject in need thereof”
- Route: “nasally administering”
- Drug actives: fixed-dose pharmaceutical composition comprising:
- mometasone furoate
- olopatadine hydrochloride
- Form/administration detail:
- 2 sprays per nostril
- twice daily
- Per-spray dosing (claimed):
- about 25 mcg mometasone furoate
- olopatadine hydrochloride “equivalent to about 600 mcg olopatadine”
- Primary performance limitation:
- twice-daily administration of the combination provides a faster onset of action than twice-daily administration of olopatadine equivalent to about 1200 mcg olopatadine per nostril alone
This claim is built around a combination dosing regimen plus a comparative “faster onset” functional limitation. Practically, it creates a target: any generic or follow-on product that matches the same MF/OLP fixed-dose spray and dose geometry and achieves the claimed onset advantage risks falling within scope.
2) Dependent claim structure: narrowing levers
Claims 2–15 add specific narrowing features:
- Formulation state (Claim 2): MF in particulate form + OLP in solution; composition is a suspension
- Duration (Claim 3): at least 1 week
- Subtype (Claims 4–5): perennial and seasonal allergic rhinitis
- Responder phenotype (Claim 6, 9): patient has positive skin prick test to an allergen
- Symptom localization (Claims 10–12, 13–15): nasal symptoms, including nasal congestion, rhinorrhea, itching, sneezing, with sneezing called out separately
3) Seasonal variant independent claim 7: tighter OLP dosing
Claim 7 mirrors claim 1 but with a distinct OLP dose specification:
- administered as 2 sprays per nostril, twice daily
- each spray includes about 25 mcg MF
- and about 665 mcg OLP hydrochloride
- faster onset comparison remains:
- faster onset than OLP alone at equivalent to 1200 mcg olopatadine (per nostril)
Claim 7 also requires the composition form as:
- suspension with MF particulate + OLP in solution.
Claim 8 adds:
- twice-daily dosing for 2 weeks.
Takeaway: US 10,646,500 has at least two independent “dose-geometry” anchors:
- claim 1: OLP per spray “equivalent” to 600 mcg olopatadine
- claim 7: OLP per spray at 665 mcg OLP HCl
Any design-around must address both the spray regimen and the dose equivalence / specific claimed amounts, plus the faster onset comparative feature.
What is the exact claimed dosing geometry (spray math that drives scope)?
Claim 1 dosing math
- Per spray: ~25 mcg MF + OLP equivalent ~600 mcg olopatadine
- Per nostril per dose (2 sprays): MF ~50 mcg + OLP equivalent ~1200 mcg olopatadine
- Twice daily total per nostril: MF ~100 mcg/day + OLP equivalent ~2400 mcg/day
- Comparison baseline in claim text: “olopatadine equivalent to about 1200 mcg olopatadine per nostril alone” (as the comparator for twice-daily OLP alone)
Claim 7 dosing math
- Per spray: ~25 mcg MF + ~665 mcg OLP hydrochloride
- Per nostril per dose (2 sprays): MF ~50 mcg + OLP ~1330 mcg OLP HCl (with “equivalent” comparator language retained in the claim)
- Twice daily total: MF ~100 mcg/day + OLP ~2660 mcg OLP HCl/day
These dose geometry constraints matter for both product formulation and for clearance/regulatory labeling pathways, because generic substitution or reformulation that shifts per-spray OLP content can move the product outside claim limits.
What does the “faster onset of action” limitation require?
US 10,646,500 is explicitly tethered to a comparative functional outcome:
- twice-daily dosing of MF+OLP provides faster onset than twice-daily dosing of OLP alone at ~1200 mcg olopatadine per nostril.
In infringement litigation, this type of limitation tends to become a tie-breaker between:
- products that match drug content and regimen but do not demonstrate the claimed onset profile; and
- products that do.
From a patent-landscape perspective, this limitation typically aligns the claim scope with the data package in the patent specification supporting the onset advantage, and it affects what a potential challenger must overcome when assessing validity or non-infringement.
What are the most actionable dependent claim constraints?
Below are the narrowing elements with direct product-development and litigation relevance.
| Claim |
Adds this limitation |
Practical impact |
| 2 |
suspension; MF particulate + OLP in solution |
Formulation design-around: changing physical form distribution |
| 3 |
treat at least 1 week |
Short-course regimen may avoid scope |
| 4 |
perennial allergic rhinitis |
Indication specificity |
| 5 |
seasonal allergic rhinitis |
Indication specificity |
| 6 |
positive skin prick test |
Patient selection; can drive narrower medical claims |
| 7 |
seasonal variant; different OLP per-spray (about 665 mcg OLP HCl) |
Dose-spec design changes could avoid |
| 8 |
2 weeks twice daily |
Course-length design-around |
| 9 |
positive skin prick test |
Patient selection |
| 10–15 |
symptom-specific nasal symptoms (congestion/rhinorrhea/itching/sneezing) |
Limits medical claim wording; impacts labeling and promotional claims |
How broad is the overall claim set?
Breadth in indication
- Claim 1 covers “allergic rhinitis” broadly (perennial and seasonal covered by dependent claims 4–5).
- Claim 7 specifically covers seasonal allergic rhinitis.
Breadth in symptoms
- Claims 10–15 restrict to nasal symptoms, and further define symptom types including sneezing.
- Claims 1–9 remain less symptom-stringent, covering “one or more symptoms,” which can be used to maintain broader coverage in enforcement.
Breadth in administration
- Both independent claims lock:
- route: nasal
- spray count: 2 sprays per nostril
- dosing frequency: twice daily
- per-spray dose geometry (MF and OLP)
The locked regimen is the main breadth-limiting factor.
Competitive patent landscape: who sits near these claims?
US 10,646,500 sits at the intersection of three patent “families” that typically cluster in this space:
- MF nasal suspension patents (corticosteroid nasal formulations)
- OLP nasal solution patents (antihistamine nasal formulations)
- MF+OLP combination patents with fixed-dose metered spray regimens and clinical outcomes like symptom improvement and onset timing
Given the claim text, the most relevant competitive landscape includes:
- fixed-dose combination formulations of MF and OLP delivered via nasal metered sprays, and
- any designs that substitute dosing amounts (e.g., 600 vs 665 mcg OLP HCl per spray), change suspension state (particulate vs dissolved), or alter onset positioning.
Landscape implications for generic entrants
To avoid claim 1 or claim 7, a generic/follow-on would generally need to:
- change per-spray MF/OLP dose enough to exit the claimed “about” ranges, or
- change spray regimen (2 sprays per nostril twice daily), or
- change formulation physical state such that MF is not “particulate” or OLP not “in solution,” or
- pivot to a different clinical message that does not support the claimed “faster onset vs OLP alone” result.
Because the claims explicitly require “faster onset” as a comparative feature, entry strategies often target either:
- non-equivalence in dosing geometry, or
- a position that onset evidence does not meet the claimed comparative performance.
Where are the likely validity pressure points?
Even without the full prosecution history in hand, the claim elements suggest typical pressure points that appear in combination-method patents:
-
Dose-spec enablement and obviousness
- MF+OLP combination regimens are a known clinical strategy in allergic rhinitis.
- The novelty often concentrates on specific dosing geometry (sprays and per-spray amounts) and comparative onset.
-
Functional “faster onset” limitation
- Functional outcome limitations can be attacked if onset metrics are not clearly attributable to the claimed regimen across relevant trials.
- They can also drive disputes over how “faster” is defined in the evidence.
-
“about” ranges
- “about 25 mcg” and “about 600 mcg” / “about 665 mcg” create scope tied to the intrinsic support and measurement method in the specification.
- Challengers frequently target the boundaries by showing meaningful differences that keep products outside the claimed range while still being therapeutically active.
Practical freedom-to-operate mapping from the claim text
High-risk infringement zones
- Products that deliver a nasal suspension with:
- MF particulate + OLP in solution
- 2 sprays per nostril twice daily
- ~25 mcg MF per spray
- OLP content matching claim 1 (600 mcg olopatadine equivalent per spray) or claim 7 (665 mcg OLP HCl per spray)
- with a clinical profile positioned as faster onset vs OLP alone
Lower-risk zones (design-around levers)
- Any change to one or more of:
- spray count/frequency
- per-spray OLP equivalence
- suspension physical state requirement (for MF particulate / OLP in solution)
- course duration (to avoid claim 3/8)
- patient selection criteria and symptom-specific claim phrasing (to avoid claims 6/9 and 10–15)
Key Takeaways
- US 10,646,500 is anchored to a fixed-dose MF+OLP nasal suspension delivered as 2 sprays per nostril twice daily.
- Claim 1 and claim 7 create two distinct dose-geometry anchors for OLP:
- claim 1: ~600 mcg olopatadine equivalent per spray
- claim 7: ~665 mcg OLP HCl per spray
- The principal enforcement lever is the “faster onset of action” comparative limitation versus OLP alone at ~1200 mcg olopatadine per nostril.
- Dependent claims add constraints on formulation state (particulate MF + OLP in solution), treatment duration, rhinitis type, skin prick test positivity, and specific nasal symptoms including sneezing.
- Competitive positioning and design-around efforts should focus on the spray regimen, per-spray dose geometry, formulation physical state, and comparative onset evidence.
FAQs
1) Is the invention a combination of MF and OLP in one product?
Yes. The claims require a fixed-dose pharmaceutical composition containing mometasone furoate and olopatadine hydrochloride delivered nasally as a metered spray.
2) What regimen is required to fit the independent claims?
Both independent claims require 2 sprays per nostril administered twice daily, with per-spray dose specifications for MF and OLP.
3) What does the patent compare for “faster onset”?
It compares twice-daily MF+OLP against twice-daily olopatadine alone at about 1200 mcg olopatadine per nostril and requires faster onset.
4) Do the claims require a suspension formulation?
Dependent claim 2 and independent claim 7 require a suspension with MF in particulate form and OLP in solution.
5) Which dependent claims narrow to seasonal/perennial and to patient phenotype?
Claims 4 and 5 narrow rhinitis subtype to perennial or seasonal. Claims 6 and 9 narrow the patient population to those with a positive skin prick test.
References
[1] United States Patent and Trademark Office. US 10,646,500.
